Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
05/17/2024 | Press release | Distributed by Public on 05/17/2024 09:04
Please select the service you want to use:
Smartlinks | TraWell Co. S.p.A. | Finance | Security Markets | Security Markets | Company News | Shareholders | Shareholder Meeting | Securities Issuers | Business Support Service Companies | Borsa Italiana | London Stock Exchange (LSE) | OTC Markets
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact